

Stille Q3 2023: Beat on sales and EBIT – positive outlook and attractive valuation

Redeye recognizes a solid Q3 report from Stille, which unveiled nuggets such as 18% y/y sales growth and EBIT margin of 16%, both slightly surpassing our estimates. The current valuation indicates EV/EBIT of 11.8 for 2023, marking a notable discount compared to historical multiples.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Stille Q3 2023: Beat on sales and EBIT - positive outlook and attractive valuation